Mark T. Drayson
About
Mark T. Drayson is a scholar working on Hematology, Molecular Biology and Oncology.
According to data from OpenAlex, Mark T. Drayson has authored 369 papers receiving a total of 14.6k indexed citations (citations by other indexed papers that have themselves been cited), including 181 papers in Hematology, 136 papers in Molecular Biology and 117 papers in Oncology. Recurrent topics in Mark T. Drayson's work include Multiple Myeloma Research and Treatments (166 papers), Protein Degradation and Inhibitors (49 papers) and Cancer Treatment and Pharmacology (44 papers). Mark T. Drayson is often cited by papers focused on Multiple Myeloma Research and Treatments (166 papers), Protein Degradation and Inhibitors (49 papers) and Cancer Treatment and Pharmacology (44 papers). Mark T. Drayson collaborates with scholars based in United Kingdom, United States and Germany. Mark T. Drayson's co-authors include Gareth J. Morgan, Faith E. Davies, Roger G. Owen, Douglas Carroll, Sue Bell, J. A. Child, Christopher Ring, Victoria E. Burns, A.R. Bradwell and Hugh D Carr-Smith and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.
In The Last Decade
Mark T. Drayson
355 papers receiving 14.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mark T. Drayson United Kingdom | 63 | 6.2k | 5.9k | 4.2k | 2.4k | 1.4k | 369 | 14.6k | ||
| Ronald L. Wilder United States | 47 | 3.7k 0.6× | 3.8k 0.6× | 2.5k 0.6× | 5.9k 2.4× | 1.5k 1.1× | 113 | 27.1k | ||
| Maurizio Cutolo Italy | 80 | 1.7k 0.3× | 2.6k 0.4× | 1.8k 0.4× | 5.4k 2.2× | 915 0.7× | 613 | 22.9k | ||
| Ernest Choy United Kingdom | 68 | 3.2k 0.5× | 2.1k 0.4× | 1.7k 0.4× | 4.1k 1.7× | 1.1k 0.8× | 352 | 19.0k | ||
| Frank Buttgereit Germany | 62 | 1.1k 0.2× | 3.4k 0.6× | 1.5k 0.4× | 2.9k 1.2× | 1.4k 1.0× | 398 | 16.2k | ||
| William B. Ershler United States | 57 | 1.9k 0.3× | 1.8k 0.3× | 2.5k 0.6× | 1.5k 0.6× | 1.0k 0.7× | 195 | 12.0k | ||
| John A. Hamilton Australia | 79 | 1.6k 0.3× | 6.6k 1.1× | 4.3k 1.0× | 9.3k 3.8× | 722 0.5× | 358 | 21.7k | ||
| Juan J. Gómez‐Reino Spain | 72 | 3.8k 0.6× | 2.5k 0.4× | 1.9k 0.4× | 5.3k 2.2× | 1.7k 1.2× | 364 | 19.8k | ||
| Paula K. Roberson United States | 51 | 2.2k 0.4× | 5.1k 0.9× | 3.9k 0.9× | 687 0.3× | 625 0.5× | 123 | 12.1k | ||
| Irving Kushner United States | 56 | 1.2k 0.2× | 3.4k 0.6× | 1.8k 0.4× | 3.3k 1.4× | 481 0.4× | 144 | 16.1k | ||
| Alice B. Gottlieb United States | 90 | 5.4k 0.9× | 2.5k 0.4× | 2.1k 0.5× | 23.1k 9.5× | 479 0.4× | 602 | 31.4k |
Countries citing papers authored by Mark T. Drayson
Since
Specialization
Citations
This map shows the geographic impact of Mark T. Drayson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark T. Drayson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark T. Drayson more than expected).
Fields of papers citing papers by Mark T. Drayson
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mark T. Drayson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark T. Drayson. The network helps show where Mark T. Drayson may publish in the future.
Co-authorship network of co-authors of Mark T. Drayson
This figure shows the co-authorship network connecting the top 25 collaborators of Mark T. Drayson. A scholar is included among the top collaborators of Mark T. Drayson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark T. Drayson. Mark T. Drayson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Drayson, Mark T., Dina Patel, Guy Pratt, et al.. (2024). Laboratory practice is central to earlier myeloma diagnosis: Utilizing a primary care diagnostic tool and laboratory guidelines integrated into haematology services. British Journal of Haematology. 204(2). 476–486.
2.
Blount, Daniel G., Naeem Khan, Laura Moyce, et al.. (2024). Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia. Molecular Cancer Therapeutics. 24(1). 93–104.
3.
Kaiser, Martin, Andrew Hall, Amy Holroyd, et al.. (2024). Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome - Long-Term Follow-up of the Ukmra Optimum/Muknine Trial. Blood. 144(Supplement 1). 3354–3354.
4.
Bowcock, Stella, Catherine Atkin, Gulnaz Iqbal, et al.. (2023). Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial. Cancers. 15(13). 3337–3337.
5.
Xie, Long, James Hodson, Beáta Hargitai, et al.. (2023). Pre-eclampsia is associated with complement pathway activation in the maternal and fetal circulation, and placental tissue. Pregnancy Hypertension. 32. 43–49.
6.
Kaiser, Martin, Andrew Hall, Katrina Walker, et al.. (2023). Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma. Journal of Clinical Oncology. 41(23). 3945–3955.
7.
Faustini, Sian, Saly Al‐Taei, Jennifer Heaney, et al.. (2023). Saliva antiviral antibody levels are detectable but correlate poorly with serum antibody levels following SARS-CoV-2 infection and/or vaccination. Journal of Infection. 87(4). 328–335.
8.
Cairns, David A., Amy Holroyd, Charlotte Pawlyn, et al.. (2022). Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial. Blood. 141(14). 1666–1674.
9.
Ramasamy, Karthik, Ross Sadler, Alison Turner, et al.. (2022). Immune response to COVID ‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response. British Journal of Haematology. 197(3). 293–301.
10.
Tute, Ruth M. de, Charlotte Pawlyn, David A. Cairns, et al.. (2022). Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. Journal of Clinical Oncology. 40(25). 2889–2900.
11.
Jenner, Matthew, Charlotte Pawlyn, Faith E. Davies, et al.. (2022). The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’ , a multicentre, open‐label, randomised, phase III trial. British Journal of Haematology. 201(2). 267–279.
12.
Shields, Adrian, Sian Faustini, Caroline Kristunas, et al.. (2021). COVID-19: Seroprevalence and Vaccine Responses in UK Dental Care Professionals. Journal of Dental Research. 100(11). 1220–1227.
13.
Heaney, Jennifer, Gulnaz Iqbal, Janet Dunn, et al.. (2020). Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study. SHILAP Revista de lepidopterología. 7(10). 1–70.
14.
Pérez-Guaita, David, Mark J. Tobin, Keith R. Bambery, et al.. (2017). Probing the action of a novel anti-leukaemic drug therapy at the single cell level using modern vibrational spectroscopy techniques. Scientific Reports. 7(1). 2649–2649.
15.
MacLennan, Calman A., Jane Birtwistle, Sian Faustini, et al.. (2016). Comparison of immune response after vaccination with polysaccharide and glycoconjugate vaccines against encapsulated bacteria between HIV-infected and HIV-non-infected adults in the UK. HIV Medicine. 17. 26–27.
16.
Southam, Andrew D., Farhat L. Khanim, Rachel E. Hayden, et al.. (2015). Drug Redeployment to Kill Leukemia and Lymphoma Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids. Cancer Research. 75(12). 2530–2540.
17.
Campbell, John P., Jennifer Heaney, Mark Cobbold, et al.. (2013). Validation of a rapid lateral-flow test for the diagnosis and monitoring of immunoglobulin free light chains: Retrospective analysis of sera from patients with plasma cell dyscrasias. Clinical Chemistry. 59(10).
18.
Lilly, Andrew J., Farhat L. Khanim, Rachel E. Hayden, et al.. (2010). Nm23-H1 Indirectly Promotes the Survival of Acute Myeloid Leukemia Blast Cells by Binding to More Mature Components of the Leukemic Clone. Cancer Research. 71(3). 1177–1186.
19.
Assi, Lakhvir K., et al.. (2010). 1139 ABNORMALLY ELEVATED SERUM FREE LIGHT CHAINS IN PATIENTS WITH LIVER DISEASE. Journal of Hepatology. 52. S440–S441.
20.
MacLennan, Calman A., Esther N. Gondwe, Chisomo Msefula, et al.. (2008). The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children. Journal of Clinical Investigation. 118(4). 1553–1562.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ronald L. Wilder Breakdown of academic impact, for papers by Maurizio Cutolo Breakdown of academic impact, for papers by Ernest Choy Breakdown of academic impact, for papers by Frank Buttgereit Breakdown of academic impact, for papers by William B. Ershler Breakdown of academic impact, for papers by John A. Hamilton Breakdown of academic impact, for papers by Juan J. Gómez‐Reino Breakdown of academic impact, for papers by Paula K. Roberson Breakdown of academic impact, for papers by Irving Kushner Breakdown of academic impact, for papers by Alice B. Gottlieb